Ideaya Biosciences (Nasdaq: IDYA) has announced its financials for second-quarter 2022, saying it has a strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of June 30, 2022, which is anticipated to fund planned operations into 2025.
It also noted that it has retained worldwide rights to IDE397, following GSK’s (LSE: GSK) waiver of its option to an exclusive license to further develop and commercialize IDE397.
Californian based Ideaya in June 2020 agreed a strategic partnership with then still called GlaxoSmithKline in synthetic lethality, an emerging field in oncology, under which the UK pharma major paid $100 million upfront.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze